Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.6601
-0.0419 (-5.97%)
At close: Jun 16, 2025, 4:00 PM
0.6430
-0.0171 (-2.59%)
Pre-market: Jun 17, 2025, 7:00 AM EDT
Vaxart Revenue
Vaxart had revenue of $20.88M in the quarter ending March 31, 2025, with 857.18% growth. This brings the company's revenue in the last twelve months to $47.40M, up 433.43% year-over-year. In the year 2024, Vaxart had annual revenue of $28.70M with 288.94% growth.
Revenue (ttm)
$47.40M
Revenue Growth
+433.43%
P/S Ratio
3.02
Revenue / Employee
$451,381
Employees
105
Market Cap
150.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.70M | 21.32M | 288.94% |
| Dec 31, 2023 | 7.38M | 7.27M | 6,796.26% |
| Dec 31, 2022 | 107.00K | -785.00K | -88.00% |
| Dec 31, 2021 | 892.00K | -3.15M | -77.95% |
| Dec 31, 2020 | 4.05M | -5.82M | -58.97% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
VXRT News
- 3 days ago - Vaxart Announces Preliminary Results of Annual Meeting of Stockholders - GlobeNewsWire
- 5 days ago - Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology - GlobeNewsWire
- 6 days ago - Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - GlobeNewsWire
- 14 days ago - Vaxart Announces Adjournment of Annual Meeting of Stockholders - GlobeNewsWire
- 18 days ago - Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 - GlobeNewsWire
- 18 days ago - Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders - GlobeNewsWire
- 19 days ago - Vaxart Answers Additional Frequently Asked Questions from Retail Investors - GlobeNewsWire
- 20 days ago - Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewsWire